BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years

13 May 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

12 May 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference

10 May 2022 15:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

05 May 2022 06:30:02 By Nasdaq GlobeNewswire

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

03 Apr 2022 07:36:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo

28 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

11 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)

08 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

24 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

27 Jan 2022 06:30:00 By Nasdaq GlobeNewswire